Oncology Clinical Trials

Clinical trials in Oncology provide an important step in discovering new treatments. You can browse the list of current clinical trials below to learn more.

Trials

Metastatic Pancreatic Ductal Adenocarcinoma Study

A Randomized, Double-Blind, Placebo-Controlled Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Subjects Previously Untreated for Metastatic Pancreatic Ductal Adenocarcinoma

Sponsor: Panbela Therapeutics
NCT05254171

Learn More >

Unresectable Locally Advanced or Metastatic Solid Tumors Study

Open-Label Phase 2 Study of Ladiratuzumab Vedotin (LV) for Unresectable Locally Advanced or Metastatic Solid Tumors (Cohorts for Prostate Cancer and Melanoma open)

Sponsor: Seagen Inc
NCT04032704

Learn More >

Relapsed/Refractory Follicular Lymphoma Study

Symphony-1: A Phase 1b/3 double-blind, randomized, active-controlled, 3-stage, biomarker adaptive study of tazemetostat or placebo in combination with lenalidomide plus rituximab in subjects with relapsed/refractory follicular lymphoma

Sponsor: Epizyme, Inc
NCT04224493

Learn More >

Relapsed/Refractory Diffuse Large B-Cell Lymphoma Study

A Phase 2/3, Multicenter Randomized Study of Rituximab-Gemcitabine Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (RR DLBCL)

Sponsor: Karyopharm Therapeutics Inc
NCT04442022

Learn More >

Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Study

The BURAN Study of Buparlisib (AN2025) In Combination With Paclitaxel Compared to Paclitaxel Alone, in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Sponsor: Adlai Nortye Biopharma Co
NCT04338399

Learn More >

Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer Study

A Phase 1b, Multicenter, Two-Part, Open-Label Study of Trastuzumab Deruxtecan, an Anti-Human Epidermal Growth Factor Receptor-2 (HER2)-ADC, in Combination with Pembrolizumab, an Anti-PD-1 Antibody, in Subjects with Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer (NSCLC)

Sponsor: Daiichi Sankyo, Inc
NCT04042701

Learn More >

Stage IV or Recurrent Non-small Cell Lung Cancer Study

A Phase 2 Randomized Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)

Sponsor: Bristol-Myers Squibb
NCT04623775

Learn More >

Locally Advanced, Unresectable, PD-L1-Selected Non-Small Cell Lung Cancer Study

A Phase 3, Randomized, Open-Label Study to Compare Ociperlimab (BGB-A1217) Plus Tislelizumab (BGB-A317) Versus Durvalumab in Patients With Locally Advanced, Unresectable, PD-L1-Selected Non-Small Cell Lung Cancer Whose Disease Has Not Progressed After Concurrent Chemoradiotherapy

Sponsor: BeiGene
NCT04866017

Learn More >

Sponsors

Ut Sponsors

HOPE Cancer Center

Hope Cancer Center

Contact

Contact UT Clinical
Scroll to Top